About Innoviva, Inc.
https://www.inva.comInnoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally.
CEO
Pavel Raifeld
Compensation Summary
(Year 2024)
Salary $503,333
Bonus $414,747
Option Awards $1,775,340
All Other Compensation $23,000
Total Compensation $2,716,420
Industry Biotechnology
Sector Healthcare
Went public October 5, 2004
Method of going public IPO
Full time employees 127
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-06-03 | Forward | 1241:1000 |
ETFs Holding This Stock
Summary
Total 210
Showing Top 3 of 210
Ratings Snapshot
Rating : B
Discounted Cash Flow 5
Return On Equity 3
Return On Assets 3
Debt To Equity 1
Price To Earnings 2
Price To Book 3
Overall Score 3
Most Recent Analyst Grades
Grade Summary
Buy 1
Overweight 1
Showing Top 2 of 2
Price Target
Target High $46
Target Low $17
Target Median $35
Target Consensus $32.67
Institutional Ownership
BLACKROCK INC.
Shares:9.63M
Value:$190.08M
BLACKROCK, INC.
Shares:9.44M
Value:$186.28M
BLACKROCK FUND ADVISORS
Shares:8.36M
Value:$165.07M
Summary
% Of Shares Owned 117.87%
Total Number Of Holders 331
Showing Top 3 of 331
Market Cap $1.26 B
52w High $22.76
52w Low $16.52
Dividend Yield 7.39%
Frequency Quarterly
P/E 11.89
Volume 593.73K
Outstanding Shares 64.34M
About Innoviva, Inc.
https://www.inva.comInnoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $107.8M ▲ | $47.45M ▼ | $89.91M ▲ | 83.4% ▲ | $1.3 ▲ | $108.48M ▲ |
| Q2-2025 | $100.28M ▲ | $138.44M ▲ | $63.69M ▲ | 63.51% ▲ | $1.01 ▲ | $83.81M ▲ |
| Q1-2025 | $88.63M ▼ | $121.22M ▲ | $-46.58M ▼ | -52.56% ▼ | $-0.74 ▼ | $-27.4M ▼ |
| Q4-2024 | $91.81M ▲ | $41.5M ▲ | $20.33M ▲ | 22.15% ▲ | $0.32 ▲ | $35.95M ▲ |
| Q3-2024 | $89.51M | $29.77M | $1.21M | 1.36% | $0.02 | $19.17M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $533.1M ▲ | $1.43B ▲ | $419.15M ▼ | $1.01B ▲ |
| Q2-2025 | $497.73M ▲ | $1.33B ▲ | $618.75M ▲ | $714.82M ▲ |
| Q1-2025 | $446.88M ▲ | $1.25B ▼ | $607.49M ▼ | $646.9M ▼ |
| Q4-2024 | $412.5M ▲ | $1.3B ▲ | $609.9M ▲ | $691.16M ▲ |
| Q3-2024 | $260.63M | $1.23B | $563.07M | $668.54M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $89.91M ▲ | $49.73M ▲ | $18.41M ▼ | $10.84M ▲ | $78.98M ▲ | $48.61M ▲ |
| Q2-2025 | $63.69M ▲ | $44.07M ▼ | $33.12M ▲ | $1.25M ▲ | $78.44M ▲ | $44.07M ▼ |
| Q1-2025 | $-46.58M ▼ | $48.62M ▼ | $-34.67M ▼ | $183K ▼ | $14.13M ▼ | $48.62M ▼ |
| Q4-2024 | $20.33M ▲ | $59.24M ▲ | $-15.48M ▼ | $573K ▲ | $44.33M ▲ | $55.24M ▲ |
| Q3-2024 | $1.21M | $48.69M | $-5.27M | $211K | $43.63M | $48.42M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 License And Other Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product | $30.00M ▲ | $50.00M ▲ | $40.00M ▼ | $30.00M ▼ |
 Royalty | $60.00M ▲ | $60.00M ▲ | $60.00M ▲ | $60.00M ▲ |
CEO
Pavel Raifeld
Compensation Summary
(Year 2024)
Salary $503,333
Bonus $414,747
Option Awards $1,775,340
All Other Compensation $23,000
Total Compensation $2,716,420
Industry Biotechnology
Sector Healthcare
Went public October 5, 2004
Method of going public IPO
Full time employees 127
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-06-03 | Forward | 1241:1000 |
ETFs Holding This Stock
Summary
Total 210
Showing Top 3 of 210
Ratings Snapshot
Rating : B
Discounted Cash Flow 5
Return On Equity 3
Return On Assets 3
Debt To Equity 1
Price To Earnings 2
Price To Book 3
Overall Score 3
Most Recent Analyst Grades
Grade Summary
Buy 1
Overweight 1
Showing Top 2 of 2
Price Target
Target High $46
Target Low $17
Target Median $35
Target Consensus $32.67
Institutional Ownership
BLACKROCK INC.
Shares:9.63M
Value:$190.08M
BLACKROCK, INC.
Shares:9.44M
Value:$186.28M
BLACKROCK FUND ADVISORS
Shares:8.36M
Value:$165.07M
Summary
% Of Shares Owned 117.87%
Total Number Of Holders 331
Showing Top 3 of 331